Saturday 17 October 2026
Export LBPS’s income statement to Excel — free account
4D pharma PLC Sponsored ADR
LBPS Healthcare Biotechnology
Revenue growth for five consecutive years.
Follow LBPS
| Dec '16 | Dec '17 | Dec '18 | Feb '19 | Dec '19 | Feb '20 | Dec '20 | Feb '21 | Dec '21 | |
|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
— | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
— | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 697.71 |
P/FCF ratio |
— | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
— | — | (6.18) | — | (11.30) | (11.30) | (9.27) | — | — |
P/Operating CF |
— | — | (68.73) | — | (24.21) | (24.94) | (6.29) | (6.69) | (51.89) |
Beneish M-Score |
— | — | — | — | (47.36) | — | (2.02) | — | — |
P/B ratio |
— | — | 3.54 | — | 21.88 | 138.85 | 4.36 | 4.63 | 31.35 |
Price to Tangible BV |
— | — | 0.00 | — | 55.76 | 0.00 | 8.87 | 9.40 | 76.45 |
EV/Sales |
— | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 692.37 |
EV/EBITDA |
— | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
— | — | 0.00 | — | (14.97) | (12.28) | (3.57) | (3.13) | (10.96) |
EV/FCF |
— | — | 0.00 | — | (14.97) | (12.28) | (3.57) | (3.03) | (10.81) |
Quick Ratio |
14.60 | 10.90 | 154.46 | 13.07 | 1.86 | 1.09 | 1.97 | 1.97 | 4.56 |
Current Ratio |
15.19 | 11.60 | 14.38 | 14.38 | 2.28 | 2.28 | 2.45 | 2.45 | 5.21 |
Net Debt/EBITDA |
5.52 | 2.58 | 1.41 | 1.45 | 0.10 | (0.03) | 0.33 | 0.33 | 0.23 |
Debt/Assets |
0.00% | 0.00% | 0.05% | 0.00% | 3.01% | 3.01% | 2.22% | 0.00% | 21.59% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.04 | 0.03 | 0.03 | 0.39 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.02 | 0.03 | 0.01 |
Operating CF/Net income |
1.29 | 0.82 | 20.28 | 1.19 | 0.95 | 0.94 | 0.89 | 0.89 | 1.19 |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | — | (0.43) | (0.38) | (0.15) | (0.13) | (0.19) |
Interest Coverage |
(36.20) | (83.96) | — | — | (501.61) | — | (5,111.46) | — | (64.13) |
| (12.11%) | (27.48%) | (0.03%) | (7.67%) | (167.65%) | (97.93%) | (87.26%) | (78.27%) | (89.48%) | |
| (11.07%) | (48.05%) | (0.02%) | (0.93%) | (74.02%) | (74.49%) | (67.82%) | (124.24%) | (59.20%) | |
ROIC |
0.00% | 0.00% | (6.27%) | (6.30%) | (91.89%) | (77.69%) | (77.94%) | (77.94%) | (96.48%) |
Return on Tangible Assets |
(13.35%) | (35.23%) | (0.21%) | (58.60%) | (218.35%) | (218.91%) | (175.09%) | (175.12%) | (100.26%) |
Average Days of Receivables |
0.00 | 0.00 | 9,381.59 | — | 9,564.63 | 9,564.63 | 2,538.60 | 2,538.60 | 4,695.69 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | — | 10,852.42% | 10,852.42% | 3,388.99% | 3,388.99% | 3,012.81% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 163.42% | — | 3,858.74% | 3,858.74% | 1,886.23% | 1,886.23% | 2,212.81% |
Intangible Assets out of Total Assets |
0.15 | 0.00 | 0.00 | 0.00 | 0.46 | 0.46 | 0.40 | 0.00 | 0.33 |
Share Based Compensation of Revenue |
— | — | 0.00% | — | 126.39% | 126.39% | 47.97% | 47.97% | 99.03% |
Graham Net Nets |
— | — | (2.00) | — | 0.01 | (0.05) | 0.06 | 0.06 | 0.01 |
Graham Number |
— | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
— | — | (3.64%) | — | (6.41%) | (5.00%) | (3.97%) | (3.74%) | (12.34%) |
Free Cash Flow Yield |
— | — | 0.00% | — | (6.64%) | (8.16%) | (26.23%) | (31.01%) | (9.18%) |
Revenue per Share |
0.00 | 0.00 | 0.03 | 0.00 | 0.00 | 0.00 | 0.05 | 0.00 | 0.03 |
Operating CF per Share |
(0.24) | (0.35) | (0.04) | (0.30) | (0.44) | 0.00 | (1.91) | 0.00 | (1.79) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | (0.01) | 0.00 | (0.02) | 0.00 | (0.01) |
Free Cash Flow per Share |
(0.24) | (0.35) | (0.04) | (0.30) | (0.45) | 0.00 | (1.93) | 0.00 | (1.80) |
Cash per Share |
1.31 | 1.04 | 0.08 | 0.42 | 0.08 | 0.00 | 0.84 | 0.00 | 0.99 |
Shareholders Equity per Share |
1.65 | 1.45 | 0.61 | 3.28 | 0.48 | 0.00 | 2.73 | 0.00 | 1.53 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
1.65 | 1.45 | 0.61 | 3.28 | 0.48 | 0.00 | 2.73 | 0.00 | 1.53 |
Free Cash Flow |
(15.74) | (22.54) | (0.29) | (0.45) | (29.38) | (29.31) | (27.50) | (27.48) | (38.19) |
Working Capital |
86.47 | 71.37 | 0.65 | 0.65 | 8.30 | 8.30 | 12.34 | 12.34 | 27.88 |
Capital Expenditures |
(2.86) | (2.81) | 0.00 | — | (0.70) | (0.63) | (0.23) | (0.21) | (0.28) |
Net Current Asset Value |
84.32 | 67.36 | (35.43) | (35.43) | 5.15 | 5.15 | 10.72 | 10.72 | 8.12 |
EV/EBIT |
— | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
— | — | 0.00 | — | 2.60 | 2.33 | 0.33 | 0.31 | 0.39 |
Price to Operating Income |
— | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.16 | 0.19 | 0.00 | — | 0.29 | 0.29 | 0.31 | 0.31 | 0.37 |
Cash ROIC |
(8.21%) | (13.92%) | (5.13%) | (8.07%) | (78.46%) | (90.34%) | (52.83%) | (52.79%) | (57.80%) |
Accounts Receivable Turnover |
0.00 | 0.00 | 0.04 | — | 0.04 | 0.04 | 0.12 | 0.14 | 0.10 |
Accounts Payable Turnover |
0.39 | 0.69 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
2.40 | 4.17 | 0.00 | — | 0.00 | — | 0.00 | — | 0.00 |
Average Days of Payables |
686.89 | 670.16 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
140.57 | 94.04 | 88.13 | — | 0.00 | — | 0.00 | — | 0.00 |
Average Receivables |
4.96 | 4.96 | 6.37 | — | 6.98 | 7.05 | 5.92 | 4.80 | 7.02 |
Average Payables |
1.94 | 1.94 | 1.23 | 0.03 | 0.84 | 1.64 | 3.09 | 4.54 | 3.11 |
Average Inventory |
0.32 | 0.32 | 0.36 | — | 0.32 | — | 0.33 | — | 0.38 |
Average Assets |
110.03 | 57.50 | 78.07 | 41.13 | 40.98 | 40.83 | 44.96 | 24.55 | 53.95 |
Average Common Equity |
100.54 | 100.54 | 49.65 | 5.00 | 18.09 | 31.05 | 34.95 | 38.97 | 35.69 |
Columns are period end dates · fundamentals updated 5 Oct 2026